243 related articles for article (PubMed ID: 16203043)
1. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome.
Korfei M; Fühlhuber V; Schmidt-Wöll T; Kaps M; Preissner KT; Blaes F
J Neuroimmunol; 2005 Dec; 170(1-2):150-7. PubMed ID: 16203043
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies in childhood opsoclonus-myoclonus syndrome.
Blaes F; Pike MG; Lang B
J Neuroimmunol; 2008 Sep; 201-202():221-6. PubMed ID: 18687475
[TBL] [Abstract][Full Text] [Related]
3. IgG subclass distribution of autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Beck S; Fühlhuber V; Krasenbrink I; Tschernatsch M; Kneifel N; Kirsten A; Jaeger C; Kaps M; Preissner KT; Lang B; Rostasy K; Blaes F
J Neuroimmunol; 2007 Apr; 185(1-2):145-9. PubMed ID: 17324472
[TBL] [Abstract][Full Text] [Related]
4. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome.
Blaes F; Fühlhuber V; Korfei M; Tschernatsch M; Behnisch W; Rostasy K; Hero B; Kaps M; Preissner KT
Ann Neurol; 2005 Aug; 58(2):313-7. PubMed ID: 15988749
[TBL] [Abstract][Full Text] [Related]
5. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS).
Krasenbrink I; Fühlhuber V; Juhasz-Boess I; Stolz E; Hahn A; Kaps M; Hero B; Blaes F
Neuropediatrics; 2007 Jun; 38(3):114-6. PubMed ID: 17985258
[TBL] [Abstract][Full Text] [Related]
6. Identification of autoantigens in pediatric opsoclonus-myoclonus syndrome.
Blaes F; Fühlhuber V; Preissner KT
Expert Rev Clin Immunol; 2007 Nov; 3(6):975-82. PubMed ID: 20477144
[TBL] [Abstract][Full Text] [Related]
7. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Fühlhuber V; Bick S; Kirsten A; Hahn A; Gerriets T; Tschernatsch M; Kaps M; Preissner KT; Blaes F; Altenkämper S
J Neuroimmunol; 2009 May; 210(1-2):87-91. PubMed ID: 19339060
[TBL] [Abstract][Full Text] [Related]
8. NK Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome.
Zar T; Tschernatsch M; Hero B; Lang B; Preissner KT; Blaes F
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e176-e179. PubMed ID: 33060390
[TBL] [Abstract][Full Text] [Related]
9. New autoantibodies in pediatric opsoclonus myoclonus syndrome.
Kirsten A; Beck S; Fühlhuber V; Kaps M; Kreutz T; Korfei M; Schmitt S; Preissner KT; Blaes F
Ann N Y Acad Sci; 2007 Sep; 1110():256-60. PubMed ID: 17911440
[TBL] [Abstract][Full Text] [Related]
10. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma.
Raffaghello L; Conte M; De Grandis E; Pistoia V
Eur J Paediatr Neurol; 2009 May; 13(3):219-23. PubMed ID: 18571942
[TBL] [Abstract][Full Text] [Related]
11. Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fcgamma receptor-dependent mechanism.
Reefman E; Horst G; Nijk MT; Limburg PC; Kallenberg CG; Bijl M
Arthritis Rheum; 2007 Oct; 56(10):3399-411. PubMed ID: 17907194
[TBL] [Abstract][Full Text] [Related]
12. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
Raffaghello L; Fuhlhuber V; Bianchi G; Conte M; Blaes F; Gambini C; Pistoia V
J Leukoc Biol; 2013 Jul; 94(1):183-91. PubMed ID: 23610147
[TBL] [Abstract][Full Text] [Related]
13. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Ding X; Yang W; Ren Q; Hu J; Yang S; Han W; Wang J; Wang X; Wang H
J Neuroinflammation; 2020 Jun; 17(1):190. PubMed ID: 32546235
[TBL] [Abstract][Full Text] [Related]
14. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen.
David K; Ollert MW; Vollmert C; Heiligtag S; Eickhoff B; Erttmann R; Bredehorst R; Vogel CW
Cancer Res; 1999 Aug; 59(15):3768-75. PubMed ID: 10446994
[TBL] [Abstract][Full Text] [Related]
15. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
[TBL] [Abstract][Full Text] [Related]
16. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.
Rudnick E; Khakoo Y; Antunes NL; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Matthay KK
Med Pediatr Oncol; 2001 Jun; 36(6):612-22. PubMed ID: 11344492
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody-mediated cytotoxicity in paediatric opsoclonus-myoclonus syndrome is dependent on ERK-1/2 phophorylation.
Fühlhuber V; Bick S; Tschernatsch M; Dharmalingam B; Kaps M; Preissner KT; Blaes F
J Neuroimmunol; 2015 Dec; 289():182-6. PubMed ID: 26616889
[TBL] [Abstract][Full Text] [Related]
18. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.
Matthay KK; Blaes F; Hero B; Plantaz D; De Alarcon P; Mitchell WG; Pike M; Pistoia V
Cancer Lett; 2005 Oct; 228(1-2):275-82. PubMed ID: 15922508
[TBL] [Abstract][Full Text] [Related]
19. Analysis of antibodies to neuronal surface antigens in adult opsoclonus-myoclonus.
Sabater L; Xifró X; Saiz A; Alberch J; Graus F
J Neuroimmunol; 2008 May; 196(1-2):188-91. PubMed ID: 18462809
[TBL] [Abstract][Full Text] [Related]
20. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies.
Hayward K; Jeremy RJ; Jenkins S; Barkovich AJ; Gultekin SH; Kramer J; Crittenden M; Matthay KK
J Pediatr; 2001 Oct; 139(4):552-9. PubMed ID: 11598603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
